Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) EBIT Margin (2019 - 2025)

Avidity Biosciences' EBIT Margin history spans 7 years, with the latest figure at 29590.47% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 2552084.0% year-over-year to 29590.47%; the TTM value through Dec 2025 reached 3977.3%, down 49986.0%, while the annual FY2025 figure was 3977.3%, 49987.0% down from the prior year.
  • EBIT Margin reached 29590.47% in Q4 2025 per RNA's latest filing, down from 1513.47% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 882.29% in Q1 2021 to a low of 29590.47% in Q4 2025.
  • Average EBIT Margin over 5 years is 4074.27%, with a median of 2152.17% recorded in 2022.
  • The largest YoY upside for EBIT Margin was 268747bps in 2025 against a maximum downside of -2552084bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 2081.37% in 2021, then rose by 8bps to 1922.17% in 2022, then plummeted by -58bps to 3043.46% in 2023, then plummeted by -34bps to 4069.63% in 2024, then plummeted by -627bps to 29590.47% in 2025.
  • Per Business Quant, the three most recent readings for RNA's EBIT Margin are 29590.47% (Q4 2025), 1513.47% (Q3 2025), and 4448.71% (Q2 2025).